



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

July 2, 2018

Corporate Relationship Department
M/s. BSE Ltd
Dalal Street, Fort
Mumbai- 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai -400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclosed herewith the Press Release for your information.

Thanking you

Yours faithfully

For NATCO Pharma Limited

M Adinarayana

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)





Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/ 4 /2018-2019

Press Release

Hyderabad, India, July 2nd, 2018

**NATCO launches fixed dose combination of Sofosbuvir-Daclatasvir drug
for Hepatitis C treatment in INDIA**

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced today that it is the first company in India to launch under its brand **Hepcinat Plus**, the generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg Tablet, for the treatment of patients with chronic hepatitis C virus (HCV) infection.

Natco has launched **Hepcinat Plus** at an MRP of INR 17,500/-, for a bottle of 28 tablets.

Forwarded for favour of publication
For NATCO Pharma Limited

M Adinarayana

**M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)**

